Previous publications of the MPBCS have described the distribution of PAM50 subtypes from transcriptomic data and their impact on survival (11, 12), showing a worse prognosis for basal-like tumors [followed by HER2-enriched (HER2E) and luminal B tumors] than for luminal A (LumA) cases, in concordance with other advanced breast cancer cohorts. Here, ERBB2 is linked to breast cancer.